# Study to Assess the Efficacy and Safety of QHRD106 Injection in Acute Ischemic Stroke.

> **NCT07396337** · PHASE2 · RECRUITING · sponsor: **Changzhou Qianhong Bio-pharma Co., Ltd.** · enrollment: 320 (estimated)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** QHRD106 Injection (Low-dose group)
- **DRUG:** QHRD106 Injection (Middle-dose group)
- **DRUG:** QHRD106 Injection (High-dose group)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07396337
- **Lead sponsor:** Changzhou Qianhong Bio-pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-19
- **Primary completion:** 2026-10-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07396337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07396337, "Study to Assess the Efficacy and Safety of QHRD106 Injection in Acute Ischemic Stroke.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07396337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*